Single-dose systemic oral fluconazole for the treatment of vaginal candidiasis.
To evaluate the acceptance of fluconazole given in a single oral dose, for the safe, effective treatment of vaginal candidiasis.
A total of 428 patients who had a first or recurrent episode of vaginal candidiasis diagnosed clinically or by culture, were offered treatment with fluconazole by 40 primary care gynecologists who were unfamiliar with fluconazole treatment of vaginal candidiasis.
The efficacy of this treatment was evaluated by both physicians and patients.
Most of the physicians (72%) and most of the patients (69%) found the drug effective in relieving or at least alleviating the signs and symptoms of the disease.
The majority of patients (83.5%) rated it better than other drugs they had received for vaginitis in the past.
No recurrences were noted at the 6-week follow-up.
Fluconazole has been found effective by physicians and patients.
Both physician willingness to use it and patient compliance are satisfactory.
Mots-clés Pascal : Vaginite, Candida albicans, Fungi Imperfecti, Fungi, Thallophyta, Pharmacocinétique, Fluconazole, Dose unique, Voie orale, Epidémiologie, Etiologie, Evaluation, Efficacité traitement, Femelle, Homme, Israël, Asie, Triazole dérivé, Appareil génital femelle pathologie, Vagin pathologie, Candidose, Mycose, Infection, Antifongique, Organisation santé
Mots-clés Pascal anglais : Vaginitis, Candida albicans, Fungi Imperfecti, Fungi, Thallophyta, Pharmacokinetics, Fluconazole, Single dose, Oral administration, Epidemiology, Etiology, Evaluation, Treatment efficiency, Female, Human, Israel, Asia, Triazole derivatives, Female genital diseases, Vaginal diseases, Candidiasis, Mycosis, Infection, Antifungal agent, Public health organization
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0361239
Code Inist : 002B02S04. Création : 12/09/1997.